Patient-Reported Outcome Measures (PROMS) in Lymphoma

被引：0

作者：

Akkad, Neha ^{[1
]}

Flowers, Christopher R. ^{[2
]}

机构：

[1] UT MD Anderson Canc Ctr, Hematol & Med Oncol Fellowship Program, Houston, TX 77030 USA

[2] UT MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

来源：

CURRENT ONCOLOGY | 2025年 / 32卷 / 05期

关键词：

lymphoma; patient-reported outcomes; quality of life; QUALITY-OF-LIFE; NON-HODGKIN-LYMPHOMA; T-CELL LYMPHOMA; CANCER-THERAPY; FUNCTIONAL ASSESSMENT; VALIDATION; QUESTIONNAIRE; RELIABILITY; RITUXIMAB; SYMPTOMS;

D O I：

10.3390/curroncol32050265

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patient-reported outcome measures (PROMs) are often used to evaluate the impact of treatment and clinical decisions on the patient experience for patients with lymphoma. Regulatory agencies have provided guidance on the use of PROMs for patient-focused drug development. Though PROMs are increasingly utilized, the way in which they are used, analyzed, and reported is heterogeneous. This systematic evidence-based review will focus on how PROMs are currently used for patients with lymphoma, what domains PROMs measure, their clinical significance, links to clinical outcomes, and what gaps need to be filled to better incorporate PROMs as endpoints in clinical trials and clinical decision-making.

引用

页数：16

共 72 条

[1] Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial [J].

Bagot, Martine ;

Kim, Youn H. ;

Ram-Wolff, Caroline ;

Dalle, Stephane ;

Mehta-Shah, Neha ;

Huen, Auris ;

Poligone, Brian ;

Zinzani, Pier Luigi ;

Geskin, Larisa J. ;

Duval-Modeste, Anne-Benedicte ;

Ortiz-Romero, Pablo L. ;

Sokol, Lubomir ;

Woei-A-Jin, Sherida ;

Beylot-Barry, Marie ;

Dereure, Olivier ;

Khodadoust, Michael S. ;

Battistella, Maxime ;

Gru, Alejandro A. ;

Moins-Teisserenc, Helene ;

Viotti, Julien ;

Paiva, Christine ;

Chammard, Agnes Boyer ;

Porcu, Pierluigi .

BLOOD, 2024, 144 :467-468

[2] Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy [J].

Balitsky, Amaris ;

Pond, G. R. ;

Davies, G. A. ;

Fraser, G. ;

Kouroukis, T. ;

Levine, M. ;

Meyer, R. M. ;

Foley, R. .

BMC CANCER, 2024, 24 (01)

[3] Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study [J].

Basch, Ethan ;

Iasonos, Alexia ;

McDonough, Tiffani ;

Barz, Allison ;

Culkin, Ann ;

Kris, Mark G. ;

Scher, Howard I. ;

Schrag, Deborah .

LANCET ONCOLOGY, 2006, 7 (11) :903-909

[4] Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes [J].

Basch, Ethan ;

Jia, Xiaoyu ;

Heller, Glenn ;

Barz, Allison ;

Sit, Laura ;

Fruscione, Michael ;

Appawu, Mark ;

Iasonos, Alexia ;

Atkinson, Thomas ;

Goldfarb, Shari ;

Culkin, Ann ;

Kris, Mark G. ;

Schrag, Deborah .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23) :1624-1632

[5] Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma [J].

Bhat, T. S. ;

Herbosa, C. M. ;

Rosenberg, A. R. ;

Sogade, O. ;

Jeffe, D. B. ;

Mehta-Shah, N. ;

Semenov, Y. R. ;

Musiek, A. C. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (02) :310-318

[6] Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [J].

Burke, John M. ;

van der Jagt, Richard H. C. ;

Kahl, Brad S. ;

Wood, Peter ;

Hawkins, Tim E. ;

MacDonald, David ;

Hertzberg, Mark ;

Simpson, David ;

Craig, Michael ;

Kolibaba, Kathryn ;

Issa, Samar ;

Munteanu, Mihaela ;

Victor, Timothy W. ;

Flinn, Ian W. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (04) :182-+

[7]

Carter GC, 2008, BLOOD, V112, P828

[8] Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) Questionnaire [J].

Cella, David ;

Jensen, Sally E. ;

Webster, Kimberly ;

Du, Hongyan ;

Lai, Jin-Shei ;

Rosen, Steven ;

Tallman, Martin S. ;

Yount, Susan .

VALUE IN HEALTH, 2012, 15 (08) :1051-1058

[9] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].

CELLA, DF ;

TULSKY, DS ;

GRAY, G ;

SARAFIAN, B ;

LINN, E ;

BONOMI, A ;

SILBERMAN, M ;

YELLEN, SB ;

WINICOUR, P ;

BRANNON, J ;

ECKBERG, K ;

LLOYD, S ;

PURL, S ;

BLENDOWSKI, C ;

GOODMAN, M ;

BARNICLE, M ;

STEWART, I ;

MCHALE, M ;

BONOMI, P ;

KAPLAN, E ;

TAYLOR, S ;

THOMAS, CR ;

HARRIS, J .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579

[10] Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness [J].

Chren, MM ;

Lasek, RJ ;

Quinn, LM ;

Mostow, EN ;

Zyzanski, SJ .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (05) :707-713

← 1 2 3 4 5 6 7 8 →